Assessment for Continuation of Projects

**RBWH Research Services**

Projects that are continuing or commencing in a COVID-19 climate should meet safety and viability criteria in line with COVID-planning.

Studies may require amendments or redesign if reasonable risks are identified with the continuation of research, and projects should only commence when safe to do so.

|  |  |
| --- | --- |
| **Project Title** |  |
| **Principal Investigator** |  |
| **Sponsor** |  |
| **RBWH Department** |  |

|  |
| --- |
| **Conduct** |
| Does the research take place in a clinical area, e.g. ward, out-patient department or day investigation unit? | **Yes** **[ ]  No** **[ ]** **Please specify:** |
| How long does a research participant spend in this environment? |  |
| Please list procedures that the participant undergoes as part of the research study (e.g. venepuncture, biopsy, imaging investigation etc) |  |
| Please list staff members **other than usual clinical staff** who would interact with the participant in the conduct of the research and estimate the time that they would spend with the research participant\*.\**Note, this information is relevant to whether a research participant or researcher would be defined as a ‘close contact’ in the event of exposure* |  |
| **Intervention** |
| Would the risks of the treatment/ intervention be expected to be higher in patients infected with SARS-CoV-2? Please explain. |  |
| **Indirect/ other Risks** |
| Please list any possible impacts of COVID-19 you have considered and how you would adapt or modify the research to accommodate these? |
| **Project Risk** | **Risk level** | **Mitigation strategies** |
| **Generic Risks – COVID-19 and Clinical Research** |  |  |
| Patients and families who are unable or unwilling to attend clinical research visits related to a pandemic | Medium  | Tele-health opportunities to be explored to enable continued engagement of patients |
| Clinical staff in research positions re-called to perform clinical duties in the event of staff shortages or pandemic response |  |  |
| Access to clinical space, administration and meeting rooms limited or restricted to provide essential services for the management of pandemic response |  |  |
| **Other Risks – this Project** |  |  |
|  |  |  |
|  |  |  |